Lipoprotein(a) as well as two oxidized phospholipids (OxPLs) are all associated with multivessel coronary artery disease detected on angiography and also linked to a higher risk of major adverse ...

Heart disease remains the number 1 cause of death among individuals worldwide. To reduce this threat, a variety of screenings are used to monitor heart health, including blood tests to check levels of ...

Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...

Cleveland: Findings from a phase 1 trial reported by a Cleveland Clinic physician show that a single dose of an experimental therapy produced greater than 94% reductions in blood levels of lipoprotein ...

Baseline lipoprotein a, or Lp(a), levels are strongly associated with major adverse cardiovascular events (MACE) in high-risk patients with elevated triglyceride levels receiving statin therapy, a new ...

Please provide your email address to receive an email when new articles are posted on . Lp(a) screening should be done once for all adults and high-risk children. Lp(a) level can help guide CVD risk ...

Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...

Jeffrey Frist was getting desperate. Diagnosed with familial hypercholesterolemia (FH) in 2012 after his first heart attack the year before, he had experienced a cardiovascular event every 11 months ...